Radar on Specialty Pharmacy

News Briefs

✦ A magistrate judge recommended dismissing a lawsuit filed by Catalyst Pharmaceuticals, Inc. against the FDA, HHS and Jacobus Pharmaceutical Company, Inc. Catalyst filed the suit (Case No. 1:19-cv-22425-BB) last ...
0 Comments
© 2025 MMIT

CMS Proposes Medicaid Best Price Changes to Boost VBP Deals

As more and more high-cost therapies come onto the U.S. market, payers are looking for ways to be able to cover those treatments for their members who need them. Value-based purchasing (VBP) arrangements are an opti...
0 Comments
© 2025 MMIT

CMS Makes COVID-Wrought Changes to Oncology Care Model

As the COVID-19 pandemic continues to spur huge changes throughout the health care system, CMS’s current and future alternative payment models have not been immune. In early June, the Center for Medicare & Med...
0 Comments
© 2025 MMIT

NSCLC Gained Seven Approvals In May; More Are in Pipeline

When the FDA approved Novartis Pharmaceuticals Corp.’s Tabrecta (capmatinib) on May 6, it was the first of seven approvals in non-small cell lung cancer (NSCLC) through May 29 (RSP 6/20, p. 8). While these will of...
0 Comments
© 2025 MMIT

Payers Say They Likely Will Cover METex14 NSCLC Agents

When the FDA approved Novartis Pharmaceuticals Corp.’s Tabrecta (capmatinib) in early May, the tablet became the first treatment approved for a specific type of non-small cell lung cancer (NSCLC). Commercial payer...
0 Comments
© 2025 MMIT

Prime Signed Value-Based Deal With EMD Serono for Mavenclad

Prime Therapeutics LLC recently unveiled that it had signed a value-based agreement for a relatively new multiple sclerosis (MS) drug with a complicated treatment regimen and high price tag. In early June, the PB...
0 Comments
© 2025 MMIT

Community Oncology Practices Are Feeling Pandemic Pressure

Community oncology practices already have been hit hard for a number of years, and the COVID-19 pandemic may make the situation worse. But as hospitals try to keep immune-compromised people out, this could result in...
0 Comments
© 2025 MMIT

New FDA Specialty Approvals

✦ May 29: The FDA expanded the label of Eli Lilly and Co.’s Cyramza (ramucirumab) to include, in combination with erlotinib, the first-line treatment of people with metastatic non-small cell lung cancer with EGF...
0 Comments
© 2025 MMIT

News Briefs

✦ A federal circuit court ruled July 6 that Amgen Inc. gave adequate notice to Roche Group unit Genentech USA, Inc. before commercializing its Mvasi (bevacizumab-awwb), a biosimilar to Genentech’s Avastin (bevac...
0 Comments
© 2025 MMIT

COVID Will Transform Cancer Care for Patients and Providers

With the novel coronavirus putting immunocompromised people in particular at risk and hospitals focusing on treating people with COVID-19, many people with cancer are experiencing disruptions in their treatment. And...
0 Comments
© 2025 MMIT